Delivery Order SPE2DB22D3016-SPE2DB24FAVM7
- Not listed
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $17,153.19, is for the delivery of YERVOY 50 MG/10 ML VIAL 10ML, a pharmaceutical product. The contract has a firm fixed-price pricing type and an ultimate completion date of April 7, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, is for the supply of the pharmaceutical product YERVOY 50 MG/10 ML VIAL 10ML. The $32,435.10 delivery order contract has a firm fixed price and will be performed in Conshohocken, Pennsylvania. The contract is being issued by the Defense Logistics Agency (DLA), which is a defense agency. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Yervoy 50 mg/10 ml vials. The award, issued on November 12, 2025, carries a ceiling value of $18,076.83 under a firm fixed-price contract type with an ultimate completion date of December 4, 2025. This is a non-set-aside competitive award, demonstrating AmerisourceBergen's capability to meet federal...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the supply of YERVOY 200 MG/40 ML VIAL 40ML, a specialty pharmaceutical product. The contract has a firm fixed price of $21,614.14 and a completion date of August 12, 2024. This contract is not designated as a set-aside. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government,...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a delivery order worth $28,401.37 for the supply of 4564589796 units of the pharmaceutical product YERVOY 50 MG/10 ML VIAL 10ML. The contract has an ultimate completion date of June 4, 2024 and was awarded on May 13, 2024. The contract is issued by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the U.S. Department of Defense, and is not designated as a set-aside. Amerisourcebergen,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Yervoy 50 mg/10 mL vials valued at $25,038.88 with a firm fixed price arrangement. This delivery order, which represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement, is scheduled for completion by January 27, 2026, and will be fulfilled from the company's Conshohocken, Pennsylvania location. The award was made through competitive...
- This federal contract award, valued at $78,114.24, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies,...
- The Defense Logistics Agency awarded a $37,864.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of YERVOY (ipilimumab) 200 mg/40 mL vials. The contract, awarded on May 12, 2025, with an ultimate completion date of June 3, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to meet federal pharmaceutical...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,415.48, is a delivery order under the company's existing Indefinite Delivery Contract (IDC) with the DLA, worth $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical...
- This is a $17,590.02 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is not set aside and runs through April 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical that serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB24FAVM7Delivery Order
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, the corporate office division of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The contract is for the supply of Yervoy 200 mg/40 ml vials, a medication used to treat certain types of cancer. The contract has a ceiling value of $68,259.74 and an ultimate completion date of June 4, 2024. This is a delivery order contract with a firm fixed price pricing type. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. Additionally, Amerisourcebergen holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $68.3k | 5/13/24 |